常山药业(300255) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥574,179,074.10, a decrease of 19.18% compared to ¥710,471,945.23 in the same period last year[4] - Net profit attributable to shareholders was ¥29,651,405.14, down 56.75% from ¥68,564,864.13 year-on-year[4] - Basic earnings per share decreased to ¥0.03, down 57.14% from ¥0.07 in the same period last year[4] - Net profit for the current period was ¥28,851,938.26, down 57.5% from ¥67,763,683.84 in the previous period[31] - The total comprehensive income for the current period was ¥27,186,973.03, down from ¥67,650,342.85 in the previous period[34] Cash Flow - The net cash flow from operating activities was -¥158,674,887.67, a decline of 312.95% compared to ¥74,511,494.41 in the previous year[4] - The cash inflow from operating activities totaled ¥570,204,153.47, a decrease of 26.3% compared to ¥773,417,974.82 in the previous period[35] - The cash outflow from operating activities amounted to ¥728,879,041.14, an increase of 4.3% from ¥698,906,480.41 in the prior period[38] - The net cash flow from investment activities was -¥143,068,776.56, compared to -¥26,001,230.73 in the previous period[38] - Cash inflow from financing activities was ¥439,130,477.50, with a net cash flow of ¥359,162,655.61 after outflows[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,597,062,348.40, an increase of 7.85% from ¥5,189,848,787.26 at the end of the previous year[4] - Current assets amounted to CNY 3,664,314,908.73, up from CNY 3,408,485,410.19 at the beginning of the year, indicating a growth of approximately 7.5%[21] - Total liabilities increased to ¥2,497,755,786.05 from ¥2,117,729,197.94, representing a growth of 17.9%[27] - Non-current liabilities rose to ¥531,455,411.42 from ¥383,684,965.68, an increase of 38.6%[27] - The company’s total liabilities increased, with short-term borrowings being a significant component of the total liabilities[21] Expenses - Total operating costs decreased to ¥542,640,735.36 from ¥629,075,497.31, reflecting a reduction of 13.7%[28] - The company experienced a 44.69% decrease in selling expenses, attributed to the reduction in sales revenue[9] - Research and development expenses for the current period were ¥36,139,354.53, a decrease of 11.5% from ¥40,999,115.40 in the previous period[28] Other Financial Metrics - The weighted average return on net assets was 0.96%, down 1.42% from 2.38% in the same period last year[4] - The company reported a foreign exchange loss of ¥1,408,421.45, compared to a loss of ¥1,360,520.62 in the previous period[31] - The total equity attributable to shareholders of the parent company was ¥3,096,770,800.59, up from ¥3,068,784,360.68, a growth of 0.9%[27] - The company reported accounts receivable of CNY 282,556,880.93, down from CNY 293,346,231.91, indicating a decrease of approximately 3%[21] Shareholder Information - The company repurchased 15,906,000 shares in 2020, accounting for 1.70% of the total share capital[14] - The total number of restricted shares at the end of the period was 253,514,027, with 168,450 shares released during the period[17]